neoIM: T-cell immunogenicity prediction
neoIM is myNEO's immunogenicity prediction algorithm. It estimates the probability that an epitope elicits a T-cell response. Candidate epitopes are ranked according to predicted CD8+ and CD4+ T-cell immunogenicity.
CD8+ and CD4+ T-cell immunogenicity
neoIM estimates the probability that an epitope elicits a T-cell response. Candidates are ranked by predicted CD8+ and CD4+ T-cell immunogenicity to support the selection of biologically relevant targets.
In published retrospective analyses, neoIM achieved up to 30% higher precision than existing predictors and identified up to 50% more clinically actionable neoantigens. Methods and trial re-analyses are in the paper.
CD8 and CD4 ranking, across programs
Class I and IICD8+ and CD4+ contexts
neoIM ranks epitopes in MHC class I and class II settings. That supports higher immunogenicity for vaccines and T-cell programs, and lower immunogenicity where biologics need to avoid T-cell help.
ImmunoEnginePeptide score inside discovery
Inside ImmunoEngine, neoIM supplies the immunogenicity score used to rank candidate antigens.
StandaloneScreening and autoimmunity
neoIM also powers myEPITOPE immunogenicity screening and mySELF autoimmune target discovery.
The evidence behind neoIM
The neoIM method and retrospective analyses of epitope selection are described in Pfitzer et al., Vaccines 2025.
What is neoIM?
neoIM is myNEO's machine-learning immunogenicity prediction algorithm. It estimates whether an epitope will elicit a T-cell response. Candidates are ranked by predicted CD8+ and CD4+ immunogenicity. In published retrospective analyses, neoIM achieved up to 30% higher precision than existing predictors and identified up to 50% more clinically actionable neoantigens.
Does neoIM cover MHC class I and class II?
Yes. neoIM predicts immunogenicity in MHC class I and class II contexts, supporting CD8+ and CD4+ T-cell ranking for vaccine and T-cell programs, and lower-immunogenicity selection for biologics where relevant.
Where is neoIM used?
neoIM is used inside ImmunoEngine to rank candidate antigens, in myEPITOPE immunogenicity screening, and in mySELF for autoimmune target discovery.